DIADIA0.43%
SPYSPY1.11%
QQQQQQ1.78%
Trending
Top trending tickerDJTDJT7.41%
RKLBRKLB25.04%
NEGGNEGG3.67%
ASTSASTS19.07%
SANTAHATSANTAHAT13.19%
FLGC10.75%
ZBCNZBCN16.93%
PYTHPYTH6.41%
TOSHITOSHI5.50%
LUNRLUNR36.89%
Top trending tickerDJTDJT7.41%
RKLBRKLB25.04%
NEGGNEGG3.67%
ASTSASTS19.07%
SANTAHATSANTAHAT13.19%
FLGC10.75%
ZBCNZBCN16.93%
PYTHPYTH6.41%
TOSHITOSHI5.50%
LUNRLUNR36.89%
homeSymbolKALA
KALA logo

KALA
KALA BIO Inc

9,753
Mkt Cap
$6.21M
Volume
2.03M
52W High
$20.60
52W Low
$0.51
PE Ratio
-0.10
KALA Fundamentals
Price
$0.6223
Prev Close
$0.5786
Open
$0.57
50D MA
$0.8672
Beta
0.84
Avg. Volume
2.18M
EPS (Annual)
-$10.15
P/B
-0.50
Rev/Employee
$0.00
Loading...
Loading...

Feed

News

Sentiment

Earnings

Fundamentals

Info

News
all
press releases
Kala Bio Stock Soars 22% After Hours As Emergency Financing Deal Averts Asset Seizure After Eye Disease Drug Trial Collapse
A rescue financing and loan settlement halted an impending asset seizure after Oxford’s default.
Stocktwits·24d ago
News Placeholder
More News
News Placeholder
KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure
KALA BIO stock plunges 88% after its KPI-012 eye disorder study fails to meet goals, forcing the company to scrap its pipeline and explore strategic options.
Zacks·2mo ago
News Placeholder
Kala Bio Stock Just Plunged 89% Today – Here’s What Happened
The firm stated that its KPI-012 failed in a mid-stage clinical trial and announced that it intends to preserve cash, including by laying off some of its workforce and deploying other cost-saving measures.
Stocktwits·3mo ago
News Placeholder
Wall Street Analysts Believe KALA BIO (KALA) Could Rally 74.73%: Here's is How to Trade
The mean of analysts' price targets for KALA BIO (KALA) points to a 74.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·4mo ago
News Placeholder
Zacks.com featured highlights include KALA, Graham, Arq and Hawkins
KALA, GHM, ARQ, and HWKN are drawing investor attention after fresh analyst coverage highlights improving outlooks.
Zacks·5mo ago
News Placeholder
Analyst Coverage Sparks Interest in These 4 Stocks Amid Volatility
New analyst coverage lifts investor interest in KALA, GHM, ARQ, and HWKN as markets grapple with rising volatility.
Zacks·5mo ago
News Placeholder
Kala Bio Stock Sinks On CEO Exit, But Retail Feels It’s An Overreaction
Kala is set to report mid-stage trial data in the second quarter for KPI-012, its experimental treatment for persistent corneal epithelial defects.
Stocktwits·10mo ago
<
...
1
>

Latest KALA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.